BNP Paribas Financial Markets Sells 173,956 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

BNP Paribas Financial Markets lessened its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 44.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 221,739 shares of the company’s stock after selling 173,956 shares during the quarter. BNP Paribas Financial Markets’ holdings in Pacira BioSciences were worth $4,178,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Sterling Capital Management LLC increased its stake in Pacira BioSciences by 779.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock valued at $26,000 after purchasing an additional 1,208 shares in the last quarter. Ancora Advisors LLC bought a new stake in Pacira BioSciences during the 4th quarter valued at $26,000. Caitlin John LLC grew its stake in shares of Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after acquiring an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Pacira BioSciences by 495.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after acquiring an additional 2,749 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in shares of Pacira BioSciences by 16.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after acquiring an additional 513 shares in the last quarter. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX opened at $24.45 on Thursday. The company’s 50-day moving average is $24.78 and its 200 day moving average is $22.25. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The company has a market capitalization of $1.13 billion, a P/E ratio of -12.04 and a beta of 0.56. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $31.67.

Analyst Upgrades and Downgrades

PCRX has been the subject of several recent analyst reports. Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and upped their target price for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. Needham & Company LLC reduced their target price on shares of Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Barclays upped their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Finally, HC Wainwright upped their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a “buy” rating in a research note on Tuesday, April 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Pacira BioSciences presently has an average rating of “Hold” and a consensus price target of $26.44.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.